What Synexa Life Sciences does

Synexa Life Sciences is a specialist biomarker and bioanalytical contract research organization (CRO) that develops, validates, and delivers complex, custom-designed assays for pharmaceutical and biotechnology clients from discovery through regulatory submission. Its service portfolio spans soluble biomarker analysis (custom panels run on MSD, LC-MS/MS, ELISA, RIA, Olink PEA), regulated bioanalysis (PK, TK, PD, and immunogenicity), mass spectrometry-based quantification of small molecules, peptides, proteins, and ADCs, ligand-binding immunoassays, Gyrolab automated nano-scale immunoassays, high-parameter flow cytometry validated to CLSI H62, ELISpot and Fluorospot, GMP/GLP-accredited radiopharmaceutical bioanalysis, GCLP-accredited genomics (qPCR, ddPCR, sequencing, ctDNA), and spatial biology/tissue imaging. The platform is delivered from three GxP-accredited laboratories in Manchester (UK), Turku (Finland), and Cape Town (South Africa), with a 16,500 sq ft dedicated mass spectrometry facility in Manchester and a radiopharmaceutical-licensed facility in Turku that has held its licence for 15+ years.\n\nThe company monetises its capability stack through project-based CRO contracts, with pricing set bespoke per study based on assay complexity, sample volume, regulatory tier (GLP/GCP/GCLP/GMP/ICH M10), platforms employed, and study duration. Sales are direct and enterprise-led, structured as multi-phase engagements spanning preclinical work through Phase III, with no public rate card. Customer segments are primarily large pharmaceutical companies and biotechnology firms developing complex modalities (ADCs, cell therapies, gene therapies, biosimilars, radiopharmaceuticals, vaccines), with named public references concentrated in mid-sized biotechs. Synexa has 150+ validated biomarker assays, what it describes as the highest number of reportable flow cytometry parameters in a single study, and 120+ scientists (60% of a 200+ total headcount).\n\nSynexa is privately held and is part of the Synexa Group corporate structure, registered in the Netherlands with wholly-owned operating subsidiaries in the UK (Synexa Life Sciences Ltd.), Finland (Synexa Life Sciences Finland OY), and South Africa (Synexa Life Sciences (Pty) Ltd.). Ownership is anchored by Gilde Healthcare, a European healthcare-focused private equity firm that has backed a stated "buy-and-build" expansion strategy executed through two acquisitions: Syrinx Bioanalytics in May 2022 (establishing the Finnish radiopharmaceutical platform) and Alderley Analytical Ltd. in October 2024 (adding UK LC-MS/MS and ligand-binding scale, along with Alderley co-founder Sally Hannam, now Scientific Director). Most recently, the company secured Gyrolab CRO certification and an early-adopter partnership with Waters Corporation for the Xevo TQ Absolute XR mass spectrometer in June 2025, alongside a My Green Lab certification at the Cape Town site. Revenue is not publicly disclosed.

Name

Synexa Life Sciences

Legal name

Synexa Group

Website

https://synexagroup.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

Synexa Life Sciences is a specialist biomarker and bioanalytical CRO with 200+ staff and 120+ scientists across three GxP-accredited laboratories in Manchester, Turku, and Cape Town, serving pharmaceutical and biotech clients from discovery through regulatory submission with assays spanning mass spectrometry, immunoassays, flow cytometry, genomics, and radiopharmaceuticals.

Ownership category

akta.pro rank

Product category

Bioanalytical Contract Research Organization (CRO)

NAICS

Scientific Research and Development Services (5417), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

akta.pro secondary industries

Clinical Research & Trial Central Laboratories (HLAFAMAL), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Biomarker analysis services
• Bioanalytical testing
• Clinical trial bioanalysis
• Mass spectrometry services
• Immunoassay development

Headquarters

HQ city

Cape Town

HQ country

South Africa

HQ region

Africa

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services (CRO): Synexa operates as a biomarker and bioanalytical CRO providing project-based contract research services to pharmaceutical and biotech companies. Services are tailored to each client's clinical development programme, spanning discovery through regulatory submission. Revenue is generated through fee-for-service project contracts, typically structured as multi-phase engagements from preclinical through Phase III clinical studies.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Synexa Life Sciences is a specialist biomarker and bioanalytical contract research organization (CRO) that develops, validates, and delivers complex custom-designed assays for pharmaceutical and biotech clients. Operating three GLP/GCP-accredited laboratories in Manchester (UK), Turku (Finland), and Cape Town (South Africa), the company supports drug development programs from discovery through regulatory submission with services spanning mass spectrometry, immunoassays, proteomics, flow cytometry, genomics, tissue imaging, and radiopharmaceutical bioanalysis.

Product overview

Synexa Life Sciences is a biomarker and bioanalytical Contract Research Organization (CRO) providing specialist laboratory services across the drug development pipeline. The company operates a platform of integrated services organized around core technology areas: Translational Science (human disease model validation), Soluble Biomarkers (custom panels using MSD, LC-MS/MS, ELISA platforms), Regulated Bioanalysis (GLP/GCP-compliant PK/PD/immunogenicity), Mass Spectrometry (LC-MS/MS), Immunoassay Services (ligand-binding assays), Olink Proteomics (proximity extension assay), Flow Cytometry (CLSI H62-validated), ELISpot/FluoroSpot, Radiopharmaceutical Bioanalysis (GMP/GLP), Genomics (GCLP qPCR/dPCR/sequencing), Tissue Imaging (spatial biology), and Dose Formulation Analysis. The company also offers specialized expertise in Autoimmune, Oncology, Vaccines, Biosimilars, ADCs, and Cell Therapies. With over 200 staff across three global laboratory locations in Manchester (UK), Turku (Finland), and Cape Town (South Africa), Synexa delivers complex, custom-designed assays supporting customers from discovery through regulatory submission. Recent acquisitions of Alderley Analytical (2024) and Syrinx Bioanalytics (2022) have expanded large-molecule bioanalysis capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Translational Science Services Human disease model validation services that generate mechanistic data from fresh patient samples to predict clinical response, guide biomarker strategy, and strengthen regulatory submissions before clinical entry. Aimed at pharmaceutical and biotech companies developing novel therapeutics.
• Soluble Biomarker Solutions Custom biomarker panel development and measurement services for target engagement, pathway modulation, disease activity, and clinical signals from Phase I through approval, using MSD, LC-MS/MS, ELISA, RIA, fluorescence, and luminescence-based technologies. Serves pharmaceutical and biotech R&D teams.
• Regulated Bioanalysis Bespoke bioanalytical method development and validation for PK, TK, PD, immunogenicity, and related endpoints, leveraging over 20 years of expertise in LC-MS/MS, MSD, and immunoassay platforms with GLP/GCP compliance for regulatory submissions. For pharma and biotech clients developing small and large molecule therapeutics.
• Mass Spectrometry Services LC-MS/MS quantification services for small molecules, peptides, proteins, and ADCs from a dedicated 16,500 sq ft UK facility, delivering ICH M10-validated PK, TK, and biomarker analysis with GLP/GCP compliance. Serves pharmaceutical, biotech, and biosimilar developers.
• Immunoassay Services Ligand-binding assay design and validation for PK, ADA, and biomarker quantification, delivering precision and GCP/GLP compliance for regulatory decision-making. Used by pharma and biotech clients across clinical development phases.
• Olink Proteomics Services Protein biomarker signature discovery using Olink's Proximity Extension Assay technology, analyzing up to 92 proteins from 1 µL with high sensitivity and specificity for biomarker discovery, patient stratification, and mechanism-of-action studies. For pharma and biotech researchers.
• Flow Cytometry Services High-parameter flow cytometry analysis validated to CLSI H62 standards for immunophenotyping rare cells, measuring target engagement, and immune function with custom panels tailored to client endpoints. For cell therapy, immuno-oncology, and vaccine developers.
• ELISpot Assay Services GCLP-compliant ELISpot assays for detecting low-frequency T-cell and B-cell responses critical for vaccine development, immunotherapy monitoring, and CAR-T assessment with sensitive cytokine detection. Used by vaccine developers, immunotherapists, and cell therapy sponsors.
• Radiopharmaceutical Bioanalysis GMP/GLP-accredited bioanalysis at the Turku facility handling Ac-225, Th-227, I-131, and other radioisotopes, with radioactive sample management, PK analysis, and immunogenicity testing; licensed for 15+ years. For radiopharmaceutical developers.
• Genomics Services GCLP-accredited genomics services including SNP detection, qPCR, ddPCR, targeted sequencing, and ctDNA quantification, supporting cell therapy bioanalysis, viral shedding studies, and pharmacogenomics. Serves cell/gene therapy and pharmacogenomics programs.
• Tissue Imaging Services Spatial biology services including multiplex immunofluorescence, super-resolution microscopy, and correlative light and electron microscopy (CLEM) to reveal cellular organisation, target engagement, and off-target effects from drug candidate selection through mechanism-of-action studies. For pharma and biotech discovery/translational teams.
• Dose Formulation Analysis GLP toxicology study support verifying formulation accuracy, concentration consistency, and shelf-life at the Manchester facility using validated analytical methods. Supports preclinical toxicology and GLP study sponsors.
• ADC Bioanalysis Solutions Comprehensive bioanalytical solutions for antibody-drug conjugate programmes covering pharmacokinetics (intact ADC, total antibody, free payload), immunogenicity profiling, mechanisms of resistance, and safety evaluation. For ADC developers.
• Cell Therapy Bioanalysis Integrated biomarker and bioanalytical solutions for cell therapy development (CAR-T and NK cell therapies) including translational science, immune monitoring, flow cytometry, proteomics, GCLP genomics, and immunogenicity assessment, with persistence monitoring via qPCR/dPCR and viral shedding studies. For cell and gene therapy developers.

Quantifiable outcome

• Highest number of reportable flow cytometry parameters in one study
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Gyros Protein TechnologiescoreTechnology or Integration · 11 June 2025Long-standing partnership with Gyros Protein Technologies for Gyrolab automated nanolitre-scale immunoassay platform. Synexa achieved official Gyrolab CRO certification in June 2025 after working closely with Gyros to validate and optimise workflows meeting highest industry standards. Partnership driven by shared commitment to innovation and excellence.
• Waters CorporationcoreTechnology or Integration · 10 June 2025Technology partnership with Waters Corporation as one of the first bioanalytical laboratories to trial the new Xevo TQ Absolute XR Mass Spectrometer at Synexa's Manchester site. The collaboration evaluated hardware and software performance across complex assays including metal chelators and oligonucleotides, with Waters Connect software enhancing data processing efficiency and regulatory compliance.
• Syrinx BioanalyticsminorStrategic or Co-development Partner · 19 May 2022Synexa acquired Finnish CRO Syrinx Bioanalytics in May 2022 to expand bioanalysis capabilities. The acquisition enhanced Synexa's service offerings, scientific expertise, and global footprint, supporting drug development in the pharma, biotech, and biosimilar sectors.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• BioAgilytix Labs: US-headquartered bioanalytical CRO specialising in large-molecule bioanalysis, immunogenicity, PK/PD, and biomarker services for pharma and biotech — directly comparable to Synexa's core offering across similar technology platforms and customer segments.
• Celerion: Early-stage clinical bioanalytical CRO providing LC-MS/MS, ligand-binding assays, and biomarker services to pharma/biotech — overlaps heavily with Synexa's regulated bioanalysis and translational science offerings.
• Pharmaron: Global CRO/CDMO offering integrated bioanalytical services including LC-MS/MS, immunoassay, and biomarker analysis for drug development — competes with Synexa in regulated bioanalysis and large-molecule support.

Broad incumbents

• Eurofins Bioanalytical Services: Part of Eurofins Scientific's global network, offering bioanalytical, biomarker, and immunogenicity services at larger scale across multiple continents — broader portfolio than Synexa but overlapping core bioanalytical capabilities.
• Charles River Laboratories: Global CRO with established bioanalytical, biomarker, and immunogenicity service lines serving pharma/biotech — offers Synexa's capabilities as part of a much larger discovery-through-manufacturing portfolio.
• Labcorp Drug Development (Fortrea): Large clinical CRO with bioanalytical laboratories supporting PK/PD, immunogenicity, and biomarker analysis — overlaps with Synexa's regulated bioanalysis but operates at significantly greater scale across full clinical development.
• IQVIA: Largest global CRO with bioanalytical and biomarker capabilities embedded in a full-service clinical development offering — competes with Synexa for biomarker and bioanalytical contracts as part of broader enterprise deals.
• ICON plc: Global CRO with bioanalytical and laboratory services for clinical trials, including biomarker and PK/PD support — overlaps with Synexa's regulated bioanalysis offerings within a much wider portfolio.
• WuXi AppTec: Global CRO/CDMO providing bioanalytical, biomarker, and laboratory services across discovery through manufacturing — directly comparable capabilities to Synexa but at much larger scale and broader service portfolio.

Regional players

• SGS Health Sciences: Global testing services network with bioanalytical and clinical trial laboratory services — comparable service mix to Synexa but operates across a broader geographic footprint with more diversified end markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCHOFrAG_smPHVJ04pR7uEOA
• LinkedInlinkedin.com/company/synexa-life-sciences
• Xx.com/synexagroup

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synexa Life Sciences